Of note, we could not identify the support for targeting IL6 and MCP1 to reduce cardiovascular disease risk that has been demonstrated in previous mendelian randomisation studies.40 41 The discrepancy for IL6 might be attributable to our approach identifying genetic proxies at the gene for the ligand, rather than its receptor. This evidence concerns the gene IL6 and cardiovascular disorder.